Aditya Lonial

Aditya Lonial asked about Beam Therapeutics' current view on peak penetration and sales for ex vivo sickle cell therapies, given recent uptake, and the market share assumptions for risto-cel, assuming its differentiated profile holds.

Answer

CEO John Evans and President Giuseppe Ciaramella responded. Giuseppe Ciaramella highlighted significant demand for risto-cel and positive market aspects, such as consistent payment. He emphasized Beam's optimized manufacturing process, with a median mobilization cycle of one, as a competitive advantage to meet demand and differentiate risto-cel.

Aditya Lonial asked for Beam's current view on peak penetration and sales for approved ex vivo sickle cell therapies, and the market share assumptions for risto-cel, assuming its differentiated profile holds.

Answer

CEO John Evans and President Giuseppe Pino Ciaramella noted significant demand for risto-cel, consistent with market intelligence, and observed that current programs face limitations in supporting demand due to manufacturing processes. They highlighted risto-cel's optimized manufacturing process, with a median mobilization cycle of one, as a competitive advantage to meet demand.